Start free

PT-141 (Bremelanotide)

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Peptide, melanocortin receptor agonist.

This page describes what PT-141 (Bremelanotide) is and its known risks. It is not medical advice and not a guide to using it. Many of these substances are prescription-only or illegal to use without a prescription. Speak to a doctor.

Class
Peptide
Legal status
Prescription only (FDA-approved as Vyleesi for HSDD)
Half-life
Several hours
Liver strain
Low
Kidney strain
Low
Converts to estrogen
None
Suppresses natural hormones
Not typically

Medical uses

What it does in the body

Other

  • Increased sexual desire/arousal
  • Independent of testosterone/estrogen pathways

Forms, half-life and detection

FormHalf-lifeReported detection window
Injectable (Subcutaneous)Several hoursUnknown

Side effects and health risks

Heart and blood vessels

  • Transient blood pressure increase
  • Flushing

Gastrointestinal

  • Nausea (common)
  • Vomiting

Other

  • Headache
  • Skin darkening with repeated use (melanocortin pathway, rare)

Related compounds

Questions

What is the half-life of PT-141 (Bremelanotide)?

About Several hours. Half-life is the time for the level in the blood to fall by half.

How long is PT-141 (Bremelanotide) detectable?

Testing windows of Unknown are reported, depending on the test and the person.

Is PT-141 (Bremelanotide) legal?

Prescription only (FDA-approved as Vyleesi for HSDD). Laws differ by country and change; check the rules where you live.

What blood tests matter with PT-141 (Bremelanotide)?

Ask a doctor which tests suit you.

What are the side effects of PT-141 (Bremelanotide)?

Heart and blood vessels: transient blood pressure increase and flushing. Gastrointestinal: nausea (common) and vomiting. Other: headache and skin darkening with repeated use (melanocortin pathway, rare).

For information only, not medical advice. MyoStats is a tracking tool used at your own discretion. Speak to a doctor before changing your training, diet, medication or anything you take.